Asciminib Elicits Safe and Durable Responses in Previously Treated CML

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Related Keywords

,Michael Mauro ,Memorial Sloan Kettering Cancer Center ,Myeloproliferative Neoplasms Program ,Ash Annual Meeting And Exposition ,Conference ,Oncology ,News ,